These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

774 related articles for article (PubMed ID: 9917118)

  • 41. A randomized, double-blind, placebo-controlled trial of combined nevirapine and zidovudine compared with nevirapine alone in the prevention of perinatal transmission of HIV in Zimbabwe.
    Thistle P; Spitzer RF; Glazier RH; Pilon R; Arbess G; Simor A; Boyle E; Chitsike I; Chipato T; Gottesman M; Silverman M
    Clin Infect Dis; 2007 Jan; 44(1):111-9. PubMed ID: 17143826
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185.
    Stiehm ER; Lambert JS; Mofenson LM; Bethel J; Whitehouse J; Nugent R; Moye J; Glenn Fowler M; Mathieson BJ; Reichelderfer P; Nemo GJ; Korelitz J; Meyer WA; Sapan CV; Jimenez E; Gandia J; Scott G; O'Sullivan MJ; Kovacs A; Stek A; Shearer WT; Hammill H
    J Infect Dis; 1999 Mar; 179(3):567-75. PubMed ID: 9952362
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Trends in perinatal transmission of HIV/AIDS in the United States.
    Lindegren ML; Byers RH; Thomas P; Davis SF; Caldwell B; Rogers M; Gwinn M; Ward JW; Fleming PL
    JAMA; 1999 Aug; 282(6):531-8. PubMed ID: 10450714
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial.
    Taha TE; Kumwenda NI; Hoover DR; Fiscus SA; Kafulafula G; Nkhoma C; Nour S; Chen S; Liomba G; Miotti PG; Broadhead RL
    JAMA; 2004 Jul; 292(2):202-9. PubMed ID: 15249569
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reduction in the risk of vertical transmission of HIV-1 associated with treatment of pregnant women with orally administered zidovudine alone.
    Simpson BJ; Shapiro ED; Andiman WA
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Feb; 14(2):145-52. PubMed ID: 9052723
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Missed opportunities for perinatal HIV prevention among HIV-exposed infants born 1996-2000, pediatric spectrum of HIV disease cohort.
    Peters V; Liu KL; Dominguez K; Frederick T; Melville S; Hsu HW; Ortiz I; Rakusan T; Gill B; Thomas P
    Pediatrics; 2003 May; 111(5 Pt 2):1186-91. PubMed ID: 12728136
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pediatric HIV clinical trials in the United States.
    Landry S
    NIAID AIDS Agenda; 1997 Nov; ():3-4. PubMed ID: 11364921
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In-utero triple antiretroviral exposure associated with decreased growth among HIV-exposed uninfected infants in Botswana.
    Powis KM; Smeaton L; Hughes MD; Tumbare EA; Souda S; Jao J; Wirth KE; Makhema J; Lockman S; Fawzi W; Essex M; Shapiro RL
    AIDS; 2016 Jan; 30(2):211-20. PubMed ID: 26684818
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study.
    Sperling RS; Shapiro DE; McSherry GD; Britto P; Cunningham BE; Culnane M; Coombs RW; Scott G; Van Dyke RB; Shearer WT; Jimenez E; Diaz C; Harrison DD; Delfraissy JF
    AIDS; 1998 Oct; 12(14):1805-13. PubMed ID: 9792381
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Successful prevention of hiv transmission from mother to infant in Brazil using a multidisciplinary team approach.
    Nogueira SA; Abreu T; Oliveira R; Araújo L; Costa T; Andrade M; Garcia Psic MF; Machado ; Rodrigues K; Mercadante R; Fernandes I; Sapia MC; Lambert JS
    Braz J Infect Dis; 2001 Apr; 5(2):78-86. PubMed ID: 11493413
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group.
    Shaffer N; Chuachoowong R; Mock PA; Bhadrakom C; Siriwasin W; Young NL; Chotpitayasunondh T; Chearskul S; Roongpisuthipong A; Chinayon P; Karon J; Mastro TD; Simonds RJ
    Lancet; 1999 Mar; 353(9155):773-80. PubMed ID: 10459957
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A risk-benefit assessment of zidovudine in the prevention of perinatal HIV transmission.
    Newell ML; Gibb DM
    Drug Saf; 1995 Apr; 12(4):274-82. PubMed ID: 7646826
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hyperlactatemia in human immunodeficiency virus-uninfected infants who are exposed to antiretrovirals.
    Noguera A; Fortuny C; Muñoz-Almagro C; Sanchez E; Vilaseca MA; Artuch R; Pou J; Jimenez R
    Pediatrics; 2004 Nov; 114(5):e598-603. PubMed ID: 15492359
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties.
    Fiscus SA; Adimora AA; Schoenbach VJ; Lim W; McKinney R; Rupar D; Kenny J; Woods C; Wilfert C
    JAMA; 1996 May; 275(19):1483-8. PubMed ID: 8622222
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team.
    Mofenson LM; Lambert JS; Stiehm ER; Bethel J; Meyer WA; Whitehouse J; Moye J; Reichelderfer P; Harris DR; Fowler MG; Mathieson BJ; Nemo GJ
    N Engl J Med; 1999 Aug; 341(6):385-93. PubMed ID: 10432323
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rapid disease progression in HIV-1 perinatally infected children born to mothers receiving zidovudine monotherapy during pregnancy. The Italian register for HIV Infection in Children.
    AIDS; 1999 May; 13(8):927-33. PubMed ID: 10371173
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Congenital anomalies and in utero antiretroviral exposure in human immunodeficiency virus-exposed uninfected infants.
    Williams PL; Crain MJ; Yildirim C; Hazra R; Van Dyke RB; Rich K; Read JS; Stuard E; Rathore M; Mendez HA; Watts DH;
    JAMA Pediatr; 2015 Jan; 169(1):48-55. PubMed ID: 25383770
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
    Jackson JB; Musoke P; Fleming T; Guay LA; Bagenda D; Allen M; Nakabiito C; Sherman J; Bakaki P; Owor M; Ducar C; Deseyve M; Mwatha A; Emel L; Duefield C; Mirochnick M; Fowler MG; Mofenson L; Miotti P; Gigliotti M; Bray D; Mmiro F
    Lancet; 2003 Sep; 362(9387):859-68. PubMed ID: 13678973
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Point-of-care capillary blood lactate measurements in human immunodeficiency virus-uninfected children with in utero exposure to human immunodeficiency virus and antiretroviral medications.
    Crain MJ; Williams PL; Griner R; Tassiopoulos K; Read JS; Mofenson LM; Rich KC;
    Pediatr Infect Dis J; 2011 Dec; 30(12):1069-74. PubMed ID: 22051859
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of zidovudine treatment in late pregnancy on HIV-1 in utero transmission.
    Taneepanichskul S; Sirinavin S; Phuapradit W; Chaturachinda K
    Aust N Z J Obstet Gynaecol; 1997 Aug; 37(3):329-31. PubMed ID: 9325519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.